BioCentury | Nov 1, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: October 2018

New Therapeutic Targets and Biomarkers: October 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during October. Therapeutic targets are defined as any protein, gene or other molecule...
BioCentury | Oct 3, 2018
Distillery Therapeutics

Cancer

INDICATION: Melanoma Patient sample, cell culture and mouse studies suggest inhibiting UBE2N, UBE2V1, UBE2V2 or FOSL1 could help treat metastatic melanoma. In tumor samples from patients, levels of UBE2N mRNA were higher in metastatic tumors...
BioCentury | May 18, 2018
Company News

Third time’s the charm for AZ hyperkalemia drug

AstraZeneca plc (LSE:AZN; NYSE:AZN) said FDA approved Lokelma sodium zirconium cyclosilicate (ZS-9) to treat hyperkalemia in adults. AZ had received two CRLs for Lokelma following manufacturing concerns (see BioCentury Extra, March 17, 2017) . The European...
BioCentury | Mar 20, 2018
Distillery Therapeutics

Cancer

...models of other SMO inhibitor-resistant cancers. TARGET/MARKER/PATHWAY: Megakaryoblastic leukemia translocation 1 (MLK1); serum response factor (c-fos...
...School of Medicine, Stanford, Calif. email: oro@stanford.edu Michael Leviten Stanford University Megakaryoblastic leukemia translocation 1 (MLK1) Serum response factor (c-fos...
BioCentury | Dec 15, 2017
Clinical News

Clementia starts Phase III of palovarotene to treat FOP

Clementia Pharmaceuticals Inc. (Montreal, Quebec) began the Phase III MOVE trial to evaluate oral palovarotene (R667) in 80 patients with fibrodysplasia ossificans progressiva (FOP). The company plans to complete enrollment by the end of next...
BioCentury | Sep 26, 2017
Distillery Therapeutics

Neurology

...ventral zona incerta could help treat sleep disorders. In mice, levels of the activation marker c-fos...
...CONTACT: Seth Blackshaw, Johns Hopkins University School of Medicine, Baltimore, Md. email: sblack@jhmi.edu Hongjiang Li Johns Hopkins University c-fos LIM...
BioCentury | Jul 31, 2017
Distillery Therapeutics

Neurology

...mouse model of AD, levels of a truncated FOSB isoform were higher and levels of c-Fos...
BioCentury | Jun 14, 2017
Distillery Therapeutics

Endocrine / Metabolic

...and malaise. In a mouse model of the indication, levels of the neuronal activation marker c-fos...
...2017 doi:10.1038/nn.4574 CONTACT: Carlos Campos, University of Washington Seattle, Seattle, Wash. email: camposca@uw.edu Hongjiang Li University of Washington c-fos Calcitonin...
BioCentury | May 25, 2017
Translation in Brief

Youthful memories

...with recombinant TIMP2 or GM-CSF, but not GAS6, induced expression of the synaptic plasticity-related gene c-fos...
BioCentury | Mar 28, 2017
Distillery Therapeutics

Cancer

...c-fos and DUSP1 could help treat CML. In patient peripheral blood monocytes (PBMCs), levels of c-fos...
...mouse model of BCR-ABL oncogene-driven CML, Gleevec plus knockout of fos and DUSP1, or plus c-fos...
...peripheral blood and bone marrow and increased survival compared with Gleevec plus normal expression of c-fos...
Items per page:
1 - 10 of 24